Ibio AI Stock Analysis
Want to see IBIO full AI Analyst Report?
Ibio (IBIO) AI Stock Analysis
Ibio
(NASDAQ:IBIO)
The score is held down primarily by weak financial performance—large ongoing losses and material cash burn despite improving revenue—and a bearish technical setup with the stock trading below key moving averages and negative MACD. Offsetting factors include a stronger balance sheet (low leverage) and positive pipeline-related corporate updates, while valuation is hard to assess due to negative earnings and no dividend data.
Ibio (IBIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $52.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 639.54K
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 1.11
- Revenue Growth
- 115.00%
- EPS Growth
- 71.61%
- Country
- US
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ibio Business Overview & Revenue Model
Company Description
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioproce...
Ibio Financial Statement Overview
Summary
Mixed fundamentals skew negative. Revenue has rebounded in the TTM period off a very small base, and the balance sheet is a relative strength with low leverage (TTM debt-to-equity ~0.03). However, profitability and cash generation remain very weak with large, persistent losses (TTM net income about -$34.9M) and ongoing cash burn (TTM operating cash flow about -$26.9M; FCF about -$27.6M).
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07M | 100.00K | 400.00K | 225.00K | 0 | 1.88M |
| Gross Profit | 584.00K | 100.00K | 400.00K | 225.00K | 0 | -1.91M |
| EBITDA | -34.07M | -31.96M | -17.04M | -14.02M | -27.85M | -25.72M |
| Net Income | -34.88M | -33.04M | -18.38M | -24.91M | -65.01M | -50.39M |
Balance Sheet | ||||||
| Total Assets | 88.65M | 99.11M | 23.18M | 28.73M | 41.21M | 99.41M |
| Cash, Cash Equivalents and Short-Term Investments | 76.65M | 88.04M | 8.58M | 14.21M | 7.33M | 33.52M |
| Total Debt | 2.07M | 2.20M | 3.51M | 4.46M | 17.07M | 25.77M |
| Total Liabilities | 10.08M | 13.40M | 8.30M | 7.41M | 25.83M | 35.92M |
| Stockholders Equity | 78.57M | 85.71M | 14.88M | 21.32M | 15.38M | 63.48M |
Cash Flow | ||||||
| Free Cash Flow | -27.59M | -23.80M | -15.32M | -18.76M | -36.17M | -44.81M |
| Operating Cash Flow | -26.94M | -23.22M | -15.30M | -18.55M | -30.44M | -37.48M |
| Investing Cash Flow | -10.96M | -32.00M | 742.00K | 906.00K | 7.01M | -5.13M |
| Financing Cash Flow | 55.22M | 103.05M | 8.93M | 24.49M | 2.30M | -6.13M |
Ibio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.96, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.97 is Neutral, neither overbought nor oversold. The STOCH value of 28.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBIO.
Ibio Risk Analysis
Ibio disclosed 62 risk factors in its most recent earnings report. Ibio reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksIbio Peers Comparison
Overall Rating
IBIO47Neutral
PULM44Neutral
NERV41Neutral
FBLG37Underperform
CMMB32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $52.71M | -2.63 | -46.75% | ― | 115.00% | 71.61% | |
| 44Neutral | $5.00M | -1.15 | -154.64% | ― | -100.00% | 29.48% | |
| 41Neutral | $107.64M | -0.08 | 167.68% | ― | ― | -1306.84% | |
| 37Underperform | $8.10M | -0.25 | -431.79% | ― | ― | 65.30% | |
| 32Underperform | $11.88M | -1.63 | -70.81% | ― | ― | 56.99% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IBIO | Ibio Inc | 0.75 | -0.34 | -31.38% | |
| NERV | Minerva Neurosciences | 2.16 | -2.14 | -49.77% | |
| PULM | Pulmatrix | 1.37 | -3.01 | -68.72% | |
| CMMB | Chemomab Therapeutics Ltd. | 1.64 | -1.06 | -39.26% | |
| ASBP | Aspire Biopharma Holdings, Inc. | 8.30 | -110.74 | -93.03% | |
| FBLG | FibroBiologics, Inc. | 0.90 | -5.99 | -86.94% |
Ibio Corporate Events
iBio Reports Positive Preclinical Data for IBIO-610
PositiveOn November 16, 2026, iBio reported extended preclinical data for IBIO-610, its long-acting Activin E-targeting antibody, from an obese non-human primate study. At week 28, body weight was 2.3% lower relative to vehicle; at week 24, total body fat, a...
iBio Shareholders Approve Governance and Capital Structure Changes
PositiveiBio, Inc. is a biotechnology company focused on developing therapeutics and vaccines using its proprietary technology platforms. The company operates in the life sciences industry and relies on equity-based incentive plans and access to capital mark...
iBio Highlights IBIO-610 Obesity Antibody Preclinical Results
PositiveOn Oct. 13, 2026, iBio reported preclinical body-composition data from an eight-week obese non-human primate study of IBIO-610, a potentially first-in-class Activin E antibody, tested alone and with the GLP-1 agonist semaglutide used for obesity. The...
iBio Highlights Breakthrough Antibody Strategy for Obesity
PositiveIn September 2026, iBio updated its corporate presentation to highlight a strategic focus on “breakthrough antibodies” for obesity and cardiometabolic diseases, positioning itself as a next-generation player beyond first-wave GLP-1 incretin therapies...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
